+44 20 8123 2220
info@marketpublishers.com

# Bevacizumab Biosimilar Market Opportunity , Sales, Price & Clinical Trials Insight 2025

https://marketpublishers.com/r/BA77F9DC75ACEN.html
Date: December 2020
Pages: 120
Price: US$ 2,000.00 (Single User License)
ID: BA77F9DC75ACEN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

'Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025' Report Highlights:

Bevacizumab Market Opportunity: > USD 12 Billion by 2025

Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars

Bevacizumab Biosimilar Available in Market: >8 Biosimilars

Bevacizumab Market Spread: US & Europe Share > 60%

Bevacizumab Branded v/s Biosimilar Insight

Avastin & Bevacizumab Biosimilar Price, Sales & Dosage Insight

Bevacizumab Patent Insight by Indication & Year

Bevacizumab is among the cusp of getting recognized as one of the most prominent drugs for the treatment of multiple types of cancer. Being an innovative approach of immunotherapy capable of neutralizing vascular endothelial growth factor, it got its fast-end approval as a first anti-angiogenic therapy by the regulatory bodies for the benefit of millions of cancer patients. The parent bio-pharmaceutical company of the drug is F. Hoffmann-La Roche AG and in the year 2004, the drug got recognized as one of the

promising immunotherapy drugs as a first-line therapy when combined with intravenous 5-fluorouracil-based chemotherapy for the treatment of the patients suffering from metastatic colorectal cancer. Application wise, the drug has extended its wings for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. Such huge segmentation of the global bevacizumab biosimilar drug tends to deliver the large percentage it is contributing to the global cancer biosimilar market.

The emergence of bevacizumab biosimilar drug for the cancer patients have burnt all the issues that were recorded in the past few years i.e. comparison of the biosimilar drugs with the reference drugs. The 20 years of experience of bevacizumab biosimilar drug in the market has achieved high comfort level and rise in overall cancer therapeutics market that was not imagined by the researchers and the patients. The drug market is witnessed to deliver high growing healthcare benefits as the opportunities related with the cancer treatment is apparently more when compared with the treatment expenses of other biological cancer treatments.

The global market of the drug has created a jinxed for the biosimilar market, thus making the researchers and the patients lean towards this mode of treatment as one of the most prominent types. In addition to this, the overall drug market in a very short period of time has come up with high valued and worthy outcome to the parent company and it is seeking towards more robust performance with novel trends in the upcoming years. The market in a very short period of time has been successful in establishing a primary goal for over-shadowing the expensive nature of the cancer treatment towards a novel approach that is cheap, affordable and as beneficial as the reference product.

The analysis of the bevacizumab biosimilar drug performance has landed high market expectations and a classification of the drug market that is 100% accurate in terms of mechanism of action, chemical properties and many more. The association of the market with strong and prominent research team of the parent company is all focused on making the drug as a solo treatment regimen with high quality in combination with other therapies so that all the current challenges could be over-come in short period of time. In addition, it is estimated that the biosimilar drug market of bevacizumab has been able to introduce a unique revolution in the entire biosimilar market, thus resulting in creating a landscape that is successful and central component to trillion dollars cancer therapeutics market.

+44 20 8123 2220
info@marketpublishers.com

# Contents

**1. BEVACIZUMAB - CURRENT MARKET OVERVIEW**

**2. BEVACIZUMAB - REIMBURSEMENT SCENARIO**

**3. BEVACIZUMAB - COMMERCIAL AVAILABILITY**

3.1 Dosage, Patent & Price Analysis – Branded v/s Biosimilar
  3.1.1 Avastin
  3.1.2 Mvasi
  3.1.3 Zirabev
  3.1.4 Aybintio
3.2 Avastin - Sales Analysis

**4. BEVACIZUMAB BIOSIMILAR MARKET ANALYSIS**

4.1 Current Market Scenario
4.2 Market Opportunities & Forecast

**5. GLOBAL BEVACIZUMAB BIOSIMILAR ONGOING CLINICAL TRIALS OUTLOOK**

5.1 Country
5.2 Indication
5.3 Patient Segment
5.4 Organization

**6. GLOBAL BEVACIZUMAB BIOSIMILAR CLINICAL INSIGHT BY PHASE**

6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III
6.9 Preregistration
6.10 Registered

+44 20 8123 2220
info@marketpublishers.com

## 7. MARKETED BEVACIZUMAB BRANDED & BIOSIMILAR DRUG CLINICAL INSIGHT

7.1 Avastin
7.2 Bevacizumab Biosimilar - KRABEVA
7.3 Bevacizumab Biosimilar - BYVASDA
7.4 Bevacizumab Biosimilar - Bevax
7.5 Bevacizumab Biosimilar - ZIRABEV
7.6 Bevacizumab Biosimilar - Mvasi
7.7 Bevacizumab Biosimilar - Bryxta
7.8 Bevacizumab Biosimilar Bevatas
7.9 Bevacizumab Biosimilar - Cizumab
7.10 Bevacizumab Biosimilar - Versavo
7.11 Bevacizumab Biosimilar - Lumiere

## 8. BEVACIZUMAB BIOSIMILAR MARKET - FUTURE OUTLOOK

## 9. COMPETITIVE LANDSCAPE

9.1 Amgen
9.2 AryoGen Pharmed
9.3 Biothera
9.4 Boehringer Ingelheim
9.5 Centus Biotherapeutics
9.6 Henlius Biotech
9.7 Innovent Biologics
9.8 Mylan
9.9 mAbxience
9.10 Outlook Therapeutics
9.11 Pfizer
9.12 Prestige Biopharma
9.13 Roche
9.14 Samsung Bio
9.15 TOT Biopharm

+44 20 8123 2220
info@marketpublishers.com

# List Of Figures

## LIST OF FIGURES

Figure 1-1: Global – Bevacizumab Market Size (US$ Billion), 2017 - 2019
Figure 1-2: Global – Bevacizumab Market Opportunity (US$ Billion), 2020 - 2025
Figure 1-3: Bevecezumab – Market Size by Region (%), 2019
Figure 1-4: Bevecezumab – Market Size by Type of Product (%), 2019
Figure 2-1: US – Average Selling Price (ASP) of Bevacizumab Products (US$/10mg), 2020
Figure 2-2: US – Reimbursed Amount of Bevacizumab Products (US$/10mg), 2020
Figure 3-1: Avastin – FDA Approval Year by Indication
Figure 3-2: Avastin – Patent Expiration Year by Region
Figure 3-3: Avastin – Price for a Supply of 4ml & Price per Unit ml Solution for Injection (US$), December'2020
Figure 3-4: Avastin – Price for a Supply of 16ml & Price per Unit ml Solution for Injection (US$), December'2020
Figure 3-5: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), December'2020
Figure 3-6: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), December'2020
Figure 3-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), December'2020
Figure 3-8: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December'2020
Figure 3-9: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), December'2020
Figure 3-10: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December'2020
Figure 3-11: Avastin's Biosimilar - FDA Approval Year
Figure 3-12: Avastin's Biosimilar - EMA Approval Year
Figure 3-13: Mvasi - Price for 4ml Supply & Price per ml of Intravenous Solution (US$), December'2020
Figure 3-14: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (US$), December'2020
Figure 3-15: Zirabev - Price for 4ml Supply & Price per unit of Intravenous Solution (US$), December'2020
Figure 3-16: Zirabev - Price for 16 ml Supply & Price per unit of Intravenous Solution (US$), December'2020

Figure 3-17: Aybintio - Price for 4ml Supply & Price per Unit of Intravenous Solution (GBP/US$), December'2020
Figure 3-18: Aybintio - Price for 16 ml Supply & Price per unit of Intravenous Solution (GBP/US$), December'2020
Figure 3-19: Bevaczumab - Price Comparision for Single Supply of 4 ml Intravenous Solution (US$), December'2020
Figure 3-20: Bevaczumab - Price Comparision for Single Supply of 16 ml Intravenous Solution (US$), December'2020
Figure 3-21: Avastin – Annual Sales Value (US$/CHF Billion), 2017 - 2019
Figure 3-22: Global – Avastin Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 3-23: US - Avastin Quarterly Sales Value (US$ Million), 2019
Figure 3-24: Avastin – Annual Sales Share by Region (US$ Billion), 2019
Figure 3-25: Avastin – Sales Share by Region (%), 2019
Figure 3-26: Global - Avastin Quarterly Sales Value (US$ Million), Q1 – Q3, 2020
Figure 3-27: Avastin – Sales Share by Region (US$ Billion), Q1 – Q3, 2020
Figure 3-28: Avastin – Sales Share by Region (%), 2019
Figure 4-1: Global – Bevacizumab Biosimilar Market Size by Product (US$ Million), 2019
Figure 4-2: Investigational Bevacizumab Biosimilars & Their Manufacturer
Figure 4-3: Global – Zirabev Market Opportunity (US$ Million), 2019 – 2026
Figure 4-4: Global – Mvasi Market Opportunity (US$ Million), 2019 – 2025
Figure 4-5: US – Mvasi Market Opportunity (US$ Million), 2019 – 2025
Figure 4-6: Global – Bevacizumab Biosimilar Market Opportunity (US$ Billion), 2020 – 2025
Figure 5-1: Global – Bevacizumab Biosimilar Clinical Trials by Country, 2020 – 2025
Figure 5-2: Global – Bevacizumab Biosimilar Clinical Trials by Indication, 2020 – 2025
Figure 5-3: Global – Bevacizumab Biosimilar Clinical Trials by Patient Segment, 2020 – 2025
Figure 5-4: Global – Bevacizumab Biosimilar Clinical Trials by Organization, 2020 – 2025
Figure 6-1: Global – Bevacizumab Biosimilar Clinical Trials by Phase, 2020 – 2025
Figure 6-2: Global – Bevacizumab Biosimilar Clinical Trials by Phase, 2020 – 2025

+44 20 8123 2220
info@marketpublishers.com

## I would like to order

Product name: Bevacizumab Biosimilar Market Opportunity , Sales, Price & Clinical Trials Insight 2025

Product link: https://marketpublishers.com/r/BA77F9DC75ACEN.html

Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/BA77F9DC75ACEN.html

## To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970